NCT06914934View on ClinicalTrials.gov

Study of High-Dose Resveratrol in Patients With Stable Ischemic Heart Disease

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

January 20, 2025

Study Completion Date

February 10, 2025

Conditions
Ischaemic Heart Desease
Interventions
DIETARY_SUPPLEMENT

High-dose resveratrol 500 mg/day

High-dose resveratrol 500 mg/day (preferably a high-bioavailability formulation, e.g., trans-resveratrol with piperine or liposomal).

OTHER

Placebo

Placebo capsules, identical in appearance and schedule.

Trial Locations (1)

630090

Center for New Medical Technologies, Novosibirsk

All Listed Sponsors
collaborator

Center for New Medical Technologies, Novosibirsk, Russia

OTHER

lead

S.LAB (SOLOWAYS)

OTHER

NCT06914934 - Study of High-Dose Resveratrol in Patients With Stable Ischemic Heart Disease | Biotech Hunter | Biotech Hunter